SYRS
Price:
$1.9926
Market Cap:
$53.42M
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced sol...[Read more]
Industry
Biotechnology
IPO Date
2016-06-30
Stock Exchange
NASDAQ
Ticker
SYRS
According to Syros Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.46. This represents a change of -6.01% compared to the average of 3.68 of the last 4 quarters.
The mean historical Current Ratio of Syros Pharmaceuticals, Inc. over the last ten years is 9.92. The current 3.46 Current Ratio has changed 3.39% with respect to the historical average. Over the past ten years (40 quarters), SYRS's Current Ratio was at its highest in in the December 2014 quarter at 48.36. The Current Ratio was at its lowest in in the March 2015 quarter at 0.
Average
9.92
Median
5.55
Minimum
3.95
Maximum
48.36
Discovering the peaks and valleys of Syros Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.02%
Maximum Annual Current Ratio = 48.36
Minimum Annual Increase = -90.53%
Minimum Annual Current Ratio = 3.95
Year | Current Ratio | Change |
---|---|---|
2023 | 3.95 | -42.45% |
2022 | 6.87 | 58.44% |
2021 | 4.33 | -30.51% |
2020 | 6.24 | 28.10% |
2019 | 4.87 | -6.52% |
2018 | 5.21 | -11.61% |
2017 | 5.89 | -34.06% |
2016 | 8.94 | 95.09% |
2015 | 4.58 | -90.53% |
2014 | 48.36 | 1.02% |
The current Current Ratio of Syros Pharmaceuticals, Inc. (SYRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
5.05
5-year avg
5.25
10-year avg
9.92
Syros Pharmaceuticals, Inc.’s Current Ratio is less than Surrozen, Inc. (6.96), less than Bolt Biotherapeutics, Inc. (4.28), less than Larimar Therapeutics, Inc. (10.93), less than Keros Therapeutics, Inc. (20.37), less than Kezar Life Sciences, Inc. (9.58), less than IDEAYA Biosciences, Inc. (17.50), less than Syndax Pharmaceuticals, Inc. (10.50), less than Xencor, Inc. (6.92), less than REGENXBIO Inc. (3.53), less than Crinetics Pharmaceuticals, Inc. (16.09), less than Black Diamond Therapeutics, Inc. (6.87), less than Stoke Therapeutics, Inc. (6.67), less than Homology Medicines, Inc. (4.19), greater than Harpoon Therapeutics, Inc. (1.89), less than Passage Bio, Inc. (7.67), less than Pasithea Therapeutics Corp. (6.20), less than Kronos Bio, Inc. (8.49), greater than Quoin Pharmaceuticals, Ltd. (3.35), less than RenovoRx, Inc. (4.39), greater than Spero Therapeutics, Inc. (2.68), greater than Coherus BioSciences, Inc. (1.21), less than Gracell Biotechnologies Inc. (7.73), less than Neoleukin Therapeutics, Inc. (15.33),
Company | Current Ratio | Market cap |
---|---|---|
6.96 | $35.87M | |
4.28 | $25.26M | |
10.93 | $433.76M | |
20.37 | $2.27B | |
9.58 | $58.01M | |
17.50 | $2.56B | |
10.50 | $1.60B | |
6.92 | $1.39B | |
3.53 | $474.22M | |
16.09 | $4.19B | |
6.87 | $207.94M | |
6.67 | $644.94M | |
4.19 | $3.02M | |
1.89 | $865.08M | |
7.67 | $39.50M | |
6.20 | $5.18M | |
8.49 | $52.61M | |
3.35 | $1.95M | |
4.39 | $25.69M | |
2.68 | $67.02M | |
1.21 | $124.43M | |
7.73 | $989.87M | |
15.33 | $8.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syros Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Syros Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Syros Pharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for Syros Pharmaceuticals, Inc. (SYRS)?
What is the highest Current Ratio for Syros Pharmaceuticals, Inc. (SYRS)?
What is the 3-year average Current Ratio for Syros Pharmaceuticals, Inc. (SYRS)?
What is the 5-year average Current Ratio for Syros Pharmaceuticals, Inc. (SYRS)?
How does the current Current Ratio for Syros Pharmaceuticals, Inc. (SYRS) compare to its historical average?